ArticleBlood advances2023
Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
Abstract read
In one paragraph
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The role of insurance status in molecular testing for thyroid nodules with indeterminate cytology.Journal of the Endocrine Society · 2026Article
- Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria.Blood advances · 2026Article
- Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020.Blood advances · 2024Article
- Air pollutant impact on disease characteristics and outcomes in patients with acute myeloid leukemia.Blood advances · 2024Article
- Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Melanie RebechiDepartment of Internal Medicine, The Ohio State University, Columbus, OH.
Jessica KohlschmidtClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Krzysztof MrózekClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-1408-5063
Deedra NicoletClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-7796-0251
Alice S MimsClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-8971-2199
James S BlachlyClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-4275-5562
Shelley OrwickDivision of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-4537-1409
Karilyn T LarkinDepartment of Internal Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0002-1898-9836
Christopher C OakesDepartment of Internal Medicine, The Ohio State University, Columbus, OH.
Andrew HantelDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA.
Andrew J CarrollDepartment of Genetics, University of Alabama at Birmingham, Birmingham, AL.
William G BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA.
Bayard L PowellDepartment of Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC.
Geoffrey L UyDivision of Oncology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-7809-0996
Richard M StoneDepartment of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA.
Richard A LarsonDepartment of Medicine, University of Chicago, Chicago, IL.ORCID 0000-0001-9168-3203
John C ByrdDepartment of Internal Medicine, University of Cincinnati, Cincinnati, OH.
Electra D PaskettDivision of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH.
Jesse J PlascakDivision of Cancer Prevention and Control, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH.
Ann-Kathrin EisfeldClara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MWake Forest NCORP Research BaseUG1CA189824 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Emily Van Meter Dressler, GLENN J LESSER · 2014 to 2026
$57.9MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MNorthwell Health NCORPUG1CA189850 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI VINCENT P VINCIGUERRA · 2014 to 2026
$13.3MWASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI MARCUCCI, GUIDO · 2009 to 2013
$11.2MOSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9MNCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6MTargeted Therapy for LeukemiaR35CA197734 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2015 to 2021
$6.6MITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R35 CA197734NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS UG1 CA189850NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233327NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233338NCI NIH HHS UG1 CA233339
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Myeloid, AcuteAdultDisease-Free SurvivalHumansRemission InductionSocial Deprivation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.